Table 1.

ADCs and their properties used in human PK prediction

ADCs	Target	mAb isotype	Drug	Linker	Average DAR (distribution)	Conjugation	Indication
DMUC5754A30	MUC‐16	Humanized IgG1	MMAE	VC	~ 3.5 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	Ovarian, pancreatic
DNIB0600A15	Napi2b	Humanized IgG1	MMAE	VC	~ 3.5 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	Ovarian, lung
DEDN6526A31	ETBR	Humanized IgG1	MMAE	VC	~ 3.5 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	Melanoma
DMOT4039A32	MsLN	Humanized IgG1	MMAE	VC	~ 3.5 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	Ovarian, Pancreatic
Polatuzumab vedotin23, 33	CD79b	Humanized IgG1	MMAE	VC	~ 3.5 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	NHL
Pinatuzumab vedotin33, 34	CD22	Humanized IgG1	MMAE	VC	~ 3.5 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	NHL
DSTP3086S35	Steap1	Humanized IgG1	MMAE	VC	~ 3.5 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	Prostate
ADC1	NR	Humanized IgG1	MMAE	VC	~ 3.5 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	NR
ADC2	NR	Humanized IgG1	MMAE	VC	~ 3.5 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	NR
T‐DM120	HER2	Humanized IgG1	DM1	MCC	~3.5 (0–8)	Through lysines	HER2 + MBC
Brentuximab vedotin19, 36	CD30	Chimeric IgG1	MMAE	VC	~4.0 (0, 2, 4, 6, 8)	Through reduced interchain disulfide bonds	HL, ALCL

ADC, antibody–drug conjugate; ALCL, anaplastic large‐cell lymphoma; DAR, drug‐antibody ratio; HER2, human epidermal growth factor 2; HL, classical Hodgkin lymphoma; IgG1, immunoglobulin‐G1; mAb, monoclonal antibody; MBC, metastatic breast cancer; MCC, 4‐[N‐maleimidomethyl] cyclohexane‐1‐carboxylate; MMAE, monomethyl auristatin E; NHL, non‐Hodgkin lymphomas; NR, not reported; PK, pharmacokinetic; VC, valine‑citrulline.